PR Newswire Clinical TrialsOriginal article
Vial Doses First Patient with Asthma in Phase 1b Study of Vial's IL-13 x TSLP, a Bispecific Antibody Designed for Twice-Yearly Dosing
Phase 1IL-13 x TSLPPositive
AI Analysis
Summary
Vial dosed the first patient in a Phase 1b study of its bispecific antibody IL-13 x TSLP for asthma, following positive Phase 1a pharmacokinetic data in healthy volunteers supporting twice-yearly dosing intervals.
Clinical Trial Data
Phase
1b
Outcome Details
First patient dosed in Phase 1b study with asthma patients; Phase 1a data in healthy volunteers (15-800 mg IV) support progression
Importance:5/10
Sentiment:
0.60
bispecific antibodyIL-13TSLPasthmaPhase 1btwice-yearly dosingType 2 inflammation
Read the original article
Published by PR Newswire Clinical Trials on October 5, 2026 3:42 PM